Managing antipsychotic-induced parkinsonism

Drug Safety

Volumn 20, Issue 3, 1999, Pages 269-275

  Mamo, David C ^a,b   Sweet, Robert A ^a   Keshavan, Matcheri S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIARRHYTHMIC AGENT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AMNESIA; CONSTIPATION; DELIRIUM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; GAIT DISORDER; HUMAN; HYPOKINESIA; INSOMNIA; MEDICAL EXAMINATION; MORBIDITY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; TACHYCARDIA; TREMOR; URINE INCONTINENCE; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

AGED; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGENTS; HUMANS; PARKINSON DISEASE, SECONDARY; PREVALENCE;

EID: 0032973854     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920030-00006     Document Type: Review

References (49)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Ach Gen Psychiatry 1988; 45: 789-96
2. Gerlach J. New antipsychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17: 289-309
3. Tandon R. Neuropharmacologic basis for clozapine's unique profile [letter]. Arch Gen Psychiatry 1993; 50: 158-9
4. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-57
5. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 1995; 120: 128-33
6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
7. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-center, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712-26
8. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125-37
9. Wilson JA, Maclennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18: 208-10
10. Casey DE. Side effect profiles of new antipsychotics. J Clin Psychiatry 1996; 57 (S11): 40-5
11. Sweet RA, Mulsant BH, Pollock BG, et al. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer's type. Am J Geriatr Psychiatry 1996; 4: 311-9
12. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175 (12): 1054-60
13. Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85-9
14. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974; 31: 58-61
15. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-2
16. Villeneuve JL. The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972; 17: 69-72
17. Sweet RA, Pollock BG, Rosen J, et al. Early detection of neuroleptic-induced parkinsonism in the elderly patients with dementia. J Geriatr Psychiatry Neurol 1994; 7: 251-4
18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 21: 211-8
19. Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci 1993; 5: 56-60
20. Caliguri MP. Portable device for quantifying parkinsonism wrist rigidity. Mov Disord 1994; 9: 57-63
21. Shriqui CL. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can J Psychiatry 1995; 40 (2 Suppl.): 38S-48S
22. Haase HJ. Extrapyramidal modifications of fine movements: a 'conditio sine qua non' of the fundamental therapeutic action of neuroleptic drugs. In: Bordeleau JM, editor. Systeme extrapyramidal et neuroleptiques. Montreal: Editions Psychiatriques 1961: 329-53
23. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991; 48: 739-45
24. Haase HJ. Clinical observations on the actions of neuroleptics. In: Haase HJ, Janssen PA, editors. The actions of neuroleptic drugs: a psychiatric, neurological, and pharmacological investigation. Amsterdam: N Holland, 1965: 1-98
25. Haase HJ, Janssen PAJ, editors. The actions of neuroleptic drugs. New York: Elsevier, 1985
26. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harvard Rev Psychiatry 1995; 2: 327-35
27. Ayd FJ. Early onset neuroleptic-induced extrapyramidal reactions: a second survey, 1961-1981. In: Coyle JT, Enna SJ, editors. Neuroleptics: neurochemical, behavioural, and clinical perspectives. New York: Raven Press, 1983: 75-92
28. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harv Rev Psychiatry 1995; 2 (6): 327-35
29. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994; 2: 204-13
30. Palmer AM, DeKosky ST. Monamine neurons in aging and Alzheimer's disease. J Neural Trans 1993; 91: 135-59
31. Branchey MH, Branchey LB, Richardson MAR. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981; 138: 608-12
32. Ayd FJ. Neuroleptics and antiparkinsonian drugs. Int Drug Ther Newsl 1971; 6: 33-6
33. Shapiro AK. Psychochemotherapy. In: Grenell RO, Gabay S, editors. Biological foundations of psychiatry. New York, Raven Press, 1971: 793-840
34. Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsych Biol Psychiatry 1997; 21: 1059-94
35. Kalish SC, Bohn R, Mogun B, et al. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995; 43 (9): 967-73
36. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22 (1): 254-9
37. Singh M. Therapeutic reversal with benztropine in schizophrenia. J Nerv Ment Dis 1975; 160: 258-66
38. Johnston EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513-27
39. DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599-60
40. Aoki F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51
41. Gianutsos G, Stewart C, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985; 110: 357-61
42. Hamlin T. Current concepts in therapy: agents for treatment of Parkinson's disease. N Engl J Med 1975; 256: 699-701
43. Yadalam KG. Drug-inducedperkinsonism. In: Keshavan MS, Kennedy JS, editors. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation, 1992: 119-29
44. Yaryura-Tobias JA, Wolpert A, Dana L, et al. Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst 1970; 31: 60-3
45. Rajput A, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982; 39: 644-6
46. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14 (5): 543-60
47. Winslow RS, Stillner V, Coons DJ, et al. Prevention of acute dystonic reactions in patients beginning high potency neuroleptics. Am J Psychiatry 1986; 143: 706-10
48. World Health Organization, Heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412
49. Barnes TRE. Comment on WHO consensus statement. Br J Psychiatry 1990; 156: 413-4